Zobrazeno 1 - 10
of 306
pro vyhledávání: '"María Hernández Rivas"'
Publikováno v:
Summa, Vol 1, Iss 2 (2019)
El manuscrito presenta un cuerpo escrito que condensa algunos elementos de la teoría del eterno retorno; como fundamento para comprender el origen de diversos fenómenos inherentes al comportamiento humano y en consecuencia al organizacional. Se con
Externí odkaz:
https://doaj.org/article/89a54a6ead5d491e8accca6f8fe78614
Autor:
Marta Anna Sobas, Amin T. Turki, Angela Villaverde Ramiro, Alberto Hernández Sánchez, Javier Martinez Elicegui, Teresa González, Raúl Azibeiro Melchor, María Abáigar, Laura Tur, Daniele Dall'Olio, Eric Sträng, Jesse M. Tettero, Gastone Castellani, Axel Benner, Konstanze Döhner, Christian Thiede, Klaus H. Metzeler, Torsten Haferlach, Frederik Damm, Rosa Ayala, Joaquín Martínez-López, Ken I Mills, Jorge Sierra, Sören Lehmann, Matteo G. Della Porta, Jiri Mayer, Dirk Reinhardt, Rubén Villoria Medina, Renate Schulze-Rath, Martje Barbus, Jesús María Hernández-Rivas, Brian J.P Huntly, Gert Ossenkoppele, Hartmut Döhner, Lars Bullinger
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Since 2017, targeted therapies combined with conventional intensive chemotherapy have started to improve outcome of patients with acute myeloid leukemia (AML). However, even before these innovations outcomes with intensive chemotherapy have improved,
Externí odkaz:
https://doaj.org/article/89bacc8433e84280a3c6e07ffa0f97ee
Autor:
Mónica del Rey González, Sohini Chakraborty, Jesús María Hernández-Sánchez, María Diez Campelo, Christopher Y. Park, Jesús María Hernández Rivas
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Treatment with the hypomethylating agent 5-azacytidine (AZA) increases survival in high-risk (HR) myelodysplastic syndrome (MDS) patients, but predicting patient response and overall survival remains challenging. To address these issues, we analyzed
Externí odkaz:
https://doaj.org/article/c7fb6c7685b74917942b55da558c1fcc
Autor:
Juan Jose Rodriguez-Sevilla, Irene Ganan-Gomez, Feiyang Ma, Kelly Chien, Monica Del Rey, Sanam Loghavi, Guillermo Montalban-Bravo, Vera Adema, Bethany Wildeman, Rashmi Kanagal-Shamanna, Alexandre Bazinet, Helen T. Chifotides, Natthakan Thongon, Xavier Calvo, Jesús María Hernández-Rivas, Maria Díez-Campelo, Guillermo Garcia-Manero, Simona Colla
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-5 (2024)
Abstract The molecular mechanisms of venetoclax-based therapy failure in patients with acute myeloid leukemia were recently clarified, but the mechanisms by which patients with myelodysplastic syndromes (MDS) acquire secondary resistance to venetocla
Externí odkaz:
https://doaj.org/article/f8ae8a5e42764717965abbcac1ae14a5
Autor:
Irene Serrano-Gonzalo, Laura López de Frutos, Carlos Lahoz-Gil, Francisco Delgado-Mateos, María Ángeles Fernández-Galán, Montserrat Morales-Conejo, María Victoria Calle-Gordo, Daiana Ibarretxe-Gerediaga, Andrés Madinaveitia-Ochoa, Antonio Albarracin-Arraigosa, José Balanzat-Muñoz, Patricia Correcher-Medina, Luis Javier García-Frade, Jesús María Hernández-Rivas, Francesca Labbadia, Jesus Miguel López-Dupla, María Luisa Lozano-Almela, Elvira Mora-Casterá, María Soledad Noya-Pereira, María Ángeles Ruíz-Guinaldo, María del Mar Tormo-Díaz, Isidro Vitoria-Miñana, Isidro Arévalo-Vargas, Marcio Andrade-Campos, Pilar Giraldo
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 18, Iss 1, Pp 1-12 (2023)
Abstract Background The availability of multiple treatments for type 1 Gaucher disease increases the need for real-life studies to evaluate treatment efficacy and safety and provide clinicians with more information to choose the best personalized the
Externí odkaz:
https://doaj.org/article/117cc15479cb4170b8e7211100fa9146
Autor:
Daniele Dall'Olio, Eric Sträng, Amin T Turki, Jesse M Tettero, Martje Barbus, Renate Schulze-Rath, Javier Martinez Elicegui, Tommaso Matteuzzi, Alessandra Merlotti, Luciana Carota, Claudia Sala, Matteo G Della Porta, Enrico Giampieri, Jesús María Hernández-Rivas, Lars Bullinger, Gastone Castellani, with the HARMONY Healthcare Alliance Consortium
Publikováno v:
PLoS Computational Biology, Vol 20, Iss 2, p e1011299 (2024)
Onco-hematological studies are increasingly adopting statistical mixture models to support the advancement of the genomically-driven classification systems for blood cancer. Targeting enhanced patients stratification based on the sole role of molecul
Externí odkaz:
https://doaj.org/article/86fa2194647b47b49d057e9ecb159191
Autor:
Juan Carlos Caballero, Julio Dávila, María López-Pavía, Esperanza Such, Teresa Bernal, Fernando Ramos, Marisa Calabuig, Jesús María Hernández Sánchez, Helena Pomares, Mercedes Sánchez Barba, María Abáigar, Bernardo González, Brayan Merchán, Reyes Sancho-Tello, Marta Callejas, Carolina Muñoz-Novas, Carlos Cerveró, Guillermo Sanz, Jesús María Hernández Rivas, María Díez Campelo;
Publikováno v:
Therapeutic Advances in Hematology, Vol 15 (2024)
Background: Erythropoiesis stimulating agents (ESAs) are the first-line therapy in patients with lower-risk myelodysplastic syndromes (LR-MDS). Some predictive factors for ESAs response have been identified. Type and number of somatic mutations have
Externí odkaz:
https://doaj.org/article/aae5bf162b0d4831a1ded6c9dd145238
Autor:
Victoria del Pozo, Irina Bobolea, Manuel J. Rial, Georgina Espigol-Frigolé, Roser Solans Laqué, Jesús María Hernández-Rivas, Elvira Mora, Astrid Crespo-Lessmann, José Luis Izquierdo Alonso, María Sandra Domínguez Sosa, Juan Maza-Solano, Belén Atienza-Mateo, David Bañas-Conejero, Abraham L. Moure, Íñigo Rúa-Figueroa
Publikováno v:
Frontiers in Immunology, Vol 14 (2024)
Eosinophil-related diseases represent a group of pathologic conditions with highly heterogeneous clinical presentation and symptoms ranging from mild to critical. Both systemic and localized forms of disease are typically treated with glucocorticoids
Externí odkaz:
https://doaj.org/article/4c7961b8003248b7b8aa47cd17031178
Autor:
Adrián Mosquera-Orgueira, Manuel Pérez-Encinas, Alberto Hernández-Sánchez, Teresa González-Martínez, Eduardo Arellano-Rodrigo, Javier Martínez-Elicegui, Ángela Villaverde-Ramiro, José-María Raya, Rosa Ayala, Francisca Ferrer-Marín, María-Laura Fox, Patricia Velez, Elvira Mora, Blanca Xicoy, María-Isabel Mata-Vázquez, María García-Fortes, Anna Angona, Beatriz Cuevas, María-Alicia Senín, Angel Ramírez-Payer, María-José Ramírez, Raúl Pérez-López, Sonia González de Villambrosía, Clara Martínez-Valverde, María-Teresa Gómez-Casares, Carmen García-Hernández, Mercedes Gasior, Beatriz Bellosillo, Juan-Luis Steegmann, Alberto Álvarez-Larrán, Jesús María Hernández-Rivas, Juan Carlos Hernández-Boluda, on behalf of the Spanish MPN Group (GEMFIN).
Publikováno v:
HemaSphere, Vol 7, Iss 1, p e818 (2023)
Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) with heterogeneous clinical course. Allogeneic hematopoietic cell transplantation remains the only curative therapy, but its morbidity and mortality require careful candidate selection. Theref
Externí odkaz:
https://doaj.org/article/b80233d27d284aceb361680826fa5bb8
Autor:
Miguel Quijada-Álamo, María Hernández-Sánchez, Ana-Eugenia Rodríguez-Vicente, Claudia Pérez-Carretero, Alberto Rodríguez-Sánchez, Marta Martín-Izquierdo, Verónica Alonso-Pérez, Ignacio García-Tuñón, José María Bastida, María Jesús Vidal-Manceñido, Josefina Galende, Carlos Aguilar, José Antonio Queizán, Isabel González-Gascón y Marín, José-Ángel Hernández-Rivas, Rocío Benito, José Luis Ordóñez, Jesús-María Hernández-Rivas
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 7, Pp 1-11 (2021)
Abstract BIRC3 is monoallelically deleted in up to 80% of chronic lymphocytic leukemia (CLL) cases harboring del(11q). In addition, truncating mutations in the remaining allele of this gene can lead to BIRC3 biallelic inactivation, which has been sho
Externí odkaz:
https://doaj.org/article/6298fa088832472aaa3af17d993dc8f6